Editorial Material
Medicine, General & Internal
Sambhawana Bhandari, Maun R. Baral, Jorge Aguilar Zanatta
Summary: Antipsychotics can be associated with temperature dysregulation, including hyperthermia and hypothermia, which can be life-threatening. Clinicians should promptly consider drug-induced hypothermia after ruling out common causes and discontinue the medication.
CUREUS JOURNAL OF MEDICAL SCIENCE
(2021)
Review
Pharmacology & Pharmacy
Adriana Stelmach, Katarzyna Guzek, Alicja Roznowska, Irena Najbar, Anna Sadakierska-Chudy
Summary: Second-generation antipsychotics, including aripiprazole, are commonly used for treating schizophrenia. Aripiprazole is a third-generation antipsychotic drug that acts on dopamine and serotonin receptors, with minimal side effects. However, some patients may have an inadequate response to aripiprazole treatment, and genetic polymorphisms, including CYP2D6, CYP3A4, CYP3A5, ABCB1, DRD2, and 5-HTRs, may influence the therapeutic effects and metabolic response to the drug. A pharmacogenetic approach may be beneficial in predicting drug response and improving the management of schizophrenia patients.
PHARMACOLOGICAL REPORTS
(2023)
Review
Pharmacology & Pharmacy
Paula Soria-Chacartegui, Gonzalo Villapalos-Garcia, Pablo Zubiaur, Francisco Abad-Santos, Dora Koller
Summary: Olanzapine, aripiprazole, and risperidone are widely used for schizophrenia treatment and can induce various adverse drug reactions. The metabolism and individual genetic polymorphisms of these drugs affect pharmacokinetics and drug responses, necessitating consideration of patient genotypes and potential drug interactions during treatment.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Pharmacology & Pharmacy
Bhanu Gupta, Kok-Seng Chee, Li-Qi Neo, Charmaine Tang, Jayaraman Hariram, Geoffrey Chern-Yee Tan, Swapna Verma, Sutapa Basu, Deva-Priya Appan, Chan-Chun Ting, Edimansyah Abdin, Jimmy Lee
Summary: The study found that adding low-dose aripiprazole did not significantly affect the overall weight of subjects, but led to significant weight loss and improvements in metabolic parameters for those on clozapine. Olanzapine group showed significant improvement in triglycerides, with trends in other metabolic parameters, while the risperidone group did not significantly improve in weight or metabolic parameters.
THERAPEUTIC ADVANCES IN PSYCHOPHARMACOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Valentino Racki, Marina Marcelic, Igor Stimac, Daniela Petric, Natalia Kucic
Summary: This study characterized the effects of haloperidol, risperidone, and aripiprazole on BV-2 microglial cells, revealing that all three antipsychotics successfully reduced the pro-inflammatory actions of the microglial cells, with aripiprazole uniquely increasing the expression of anti-inflammatory markers. The most significant differences in possible mechanisms of action were observed in real-time metabolic assays and mTORC1 signaling pathway activity, with aripiprazole being the only antipsychotic to reduce mTORC1 activity. These results provide new insights into the effects of haloperidol, risperidone, and aripiprazole on microglial cells, suggesting a novel potential mechanism of action for aripiprazole.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Clinical Neurology
Matthew Harlin, Craig Chepke, Frank Larsen, Karimah S. Bell Lynum, Sanjeda R. Chumki, Heather Fitzgerald, Pedro Such, Jessica Madera-McDonough, Murat Yildirim, Moeen Panni, Stephen R. Saklad
Summary: Aripiprazole 2-month ready-to-use 960 mg and Aripiprazole lauroxil 1064 mg are both long-acting injectable formulations used for the treatment of schizophrenia. Comparing the drug concentrations, both formulations maintain therapeutic levels over the 2-month dosing interval.
NEUROPSYCHIATRIC DISEASE AND TREATMENT
(2023)
Article
Psychiatry
Satoko Sumi, Takahiko Nagamine, Koji Sumi, Reona Aijima, Kyoko Oka, Akira Toyofuku
Summary: Long-term observation of orthodontically treated patients revealed that open bite is influenced by the dosage of aripiprazole, worsening with increasing dosage and improving with decreasing dosage. Physicians and dentists need to be aware of this potential side effect when prescribing aripiprazole to children and adolescents.
FRONTIERS IN PSYCHIATRY
(2022)
Article
Behavioral Sciences
Richard Houghton, Joop van den Bergh, Kiely Law, Yutong Liu, Frank de Vries
Summary: This study compared the risk of bone fractures among 6624 children with autism spectrum disorder (ASD), half of whom used risperidone and half of whom used aripiprazole. Taking other factors into account, risks were similar between the two groups throughout the first 180 days on treatment, but significantly higher in the aripiprazole group thereafter. The biggest differences were in lower leg and ankle fractures. Overall, compared with aripiprazole, risperidone was associated with 40% lower risk of fracture.
Article
Psychiatry
Joseph P. McEvoy, Peter J. Weiden, Paul H. Lysaker, Xiaowu Sun, Amy K. O'Sullivan
Summary: This post hoc analysis evaluated long-term self-reported mental and physical health-related quality of life scores in schizophrenia patients receiving aripiprazole lauroxil. The results showed gradual improvement in mental health scores over several years of follow-up among patients with schizophrenia on LAI antipsychotic, while physical health scores remained stable. Schizophrenia patients had mental health scores comparable to the general population and higher than patients with depression by the end of follow-up.
Review
Psychiatry
Yuki Furukawa, Tasnim Hamza, Andrea Cipriani, Toshi A. Furukawa, Georgia Salanti, Edoardo G. Ostinelli
Summary: A meta-analysis of multiple studies suggests that low-dose aripiprazole augmentation may achieve a better balance of efficacy, tolerability, and acceptability in the acute treatment of antidepressant-refractory depression. Further research is needed to investigate the benefits of low versus high dose due to limitations in the current evidence.
BRITISH JOURNAL OF PSYCHIATRY
(2022)
Article
Psychiatry
L. A. Stabell, E. Johnsen, R. A. Kroken, E. M. Loberg, A. Blindheim, I. Joa, S. K. Reitan, M. Rettenbacher, P. Munk-Jorgensen, R. Gjestad
Summary: This study investigates the impact of antipsychotic treatment on clinical insight. It finds that antipsychotics, such as amisulpride and olanzapine, can improve insight over and above the reduction in total psychosis symptoms. However, the effect on insight compared to the effect of symptom reduction is still uncertain.
Article
Pharmacology & Pharmacy
Svetlina S. Vasileva, Jack Tucker, Dan Siskind, Darryl Eyles
Summary: The gut microbiome may mediate antipsychotic-induced side effects in patients with schizophrenia. Microbiome-focused treatments should be used in combination with standard therapy to improve debilitating drug side effects, enhance quality of life, and potentially improve psychotic symptoms.
EXPERT OPINION ON DRUG SAFETY
(2022)
Article
Biochemistry & Molecular Biology
Barbara Kramar, Tinkara Pirc Marolt, Maria Monsalve, Dusan Suput, Irina Milisav
Summary: The study reveals that aripiprazole, in contrast to olanzapine, can protect liver cells against oxidative stress, which could be crucial for schizophrenia patients with high-oxidative-stress-risk lifestyles.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Psychiatry
Maria S. Neumeier, Stephanie Homan, Stefan Vetter, Erich Seifritz, John M. Kane, Maximilian Huhn, Stefan Leucht, Philipp Homan
Summary: The variability in side effects of antipsychotic drugs is significant in the treatment of schizophrenia spectrum disorders, potentially leading to treatment nonadherence among patients. Research indicates marked differences in side effects among individual antipsychotic drugs, suggesting that personalized or stratified medicine allocation may benefit certain patient subgroups or individuals.
SCHIZOPHRENIA BULLETIN
(2021)
Article
Clinical Neurology
Marcos Gomez-Revuelta, Jose Maria Pelayo-Teran, Javier Vazquez-Bourgon, Victor Ortiz-Garcia de la Foz, Jacqueline Mayoral-van Son, Rosa Ayesa-Arriola, Benedicto Crespo-Facorro
Summary: This study compared the effectiveness of aripiprazole and risperidone in the acute-phase treatment of FEP and found no differences in treatment discontinuation rates and mean time until discontinuation between the two drugs. However, risperidone showed better performance in terms of clinical efficacy, but patients on risperidone were more likely to experience sex-related adverse events.
EUROPEAN NEUROPSYCHOPHARMACOLOGY
(2021)
Article
Substance Abuse
Fumihiko Ueno, Sachio Matsushita, Sachiko Hara, Shunji Oshima, Sungwon Roh, Vijay A. Ramchandani, Masaru Mimura, Hiroyuki Uchida
Summary: The study found that exposure to acetaldehyde following acute intravenous alcohol appears to have a negative impact on sustained attention and working memory, whereas there seems to be only a minor effect of moderate alcohol concentration on speed and accuracy.
Article
Pharmacology & Pharmacy
Mohamed Ismail, Thomas Straubinger, Hiroyuki Uchida, Ariel Graff-Guerrero, Shinichiro Nakajima, Takefumi Suzuki, Fernando Caravaggio, Philip Gerretsen, David Mamo, Benoit H. Mulsant, Bruce G. Pollock, Robert Bies
Summary: The study developed a software tool for predicting dopamine D-2 receptor occupancy using sparse plasma concentration measurements, providing clinicians with a convenient way to explore treatment strategies in patients with schizophrenia. The software demonstrates high accuracy and accessibility.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
(2022)
Article
Pharmacology & Pharmacy
Kohei Kitagawa, Ryuhei So, Nobuyuki Nomura, Masaru Tsukahara, Fuminari Misawa, Masafumi Kodama, Hiroyuki Uchida, Robert Bies, Thomas Straubinger, Christopher Banker, Yuya Mizuno, Masaru Mimura, Hiroyoshi Takeuchi
Summary: This study compared the actual plasma concentrations of clozapine between once-daily and divided dosing regimens, and examined their relationships with psychiatric symptoms and adverse effects. The results showed no significant differences in actual plasma concentrations or psychiatric symptoms between the two dosing strategies, suggesting that once-daily dosing of clozapine may be feasible and clinically useful.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
(2022)
Article
Neurosciences
Ryo Ochi, Eric Plitman, Raihaan Patel, Ryosuke Tarumi, Yusuke Iwata, Sakiko Tsugawa, Julia Kim, Shiori Honda, Yoshihiro Noda, Hiroyuki Uchida, Gabriel A. Devenyi, Masaru Mimura, Ariel Graff-Guerrero, M. Mallar Chakravarty, Shinichiro Nakajima
Summary: The study identified reproducible abnormalities in ACC structures in patients with treatment-resistant and clozapine-resistant schizophrenia, indicating a common biological feature of treatment resistance related to ACC structure and glutamate levels.
JOURNAL OF PSYCHIATRY & NEUROSCIENCE
(2022)
Review
Biochemistry & Molecular Biology
Tomomi Nakahara, Sakiko Tsugawa, Yoshihiro Noda, Fumihiko Ueno, Shiori Honda, Megumi Kinjo, Hikari Segawa, Nobuaki Hondo, Yukino Mori, Honoka Watanabe, Kazuho Nakahara, Kazunari Yoshida, Masataka Wada, Ryosuke Tarumi, Yusuke Iwata, Eric Plitman, Sho Moriguchi, Camilo de La Fuente-Sandoval, Hiroyuki Uchida, Masaru Mimura, Ariel Graff-Guerrero, Shinichiro Nakajima
Summary: The meta-analyses in this study showed increased levels of glutamatergic metabolites and reduced levels of GABA in patients with schizophrenia, indicating a possible relationship between the disruption of excitatory/inhibitory balance and the pathophysiology of schizophrenia-spectrum disorders.
MOLECULAR PSYCHIATRY
(2022)
Review
Pharmacology & Pharmacy
Hitoshi Sakurai, Kengo Yonezawa, Hideaki Tani, Masaru Mimura, Michael Bauer, Hiroyuki Uchida
Summary: This study systematically searched for antidepressant compounds with completed phase II and III trials and identified nine compounds that showed positive results, including those with novel mechanisms of action. If preliminary results are confirmed, these compounds are expected to provide more options for the treatment of depression.
PHARMACOPSYCHIATRY
(2022)
Article
Pharmacology & Pharmacy
Shin Kuramochi, Taisuke Yatomi, Takahito Uchida, Hiroyoshi Takeuchi, Masaru Mimura, Hiroyuki Uchida
Summary: This study investigated combined prescriptions of drugs for mood disorders and physical comorbidities that need special attention. The results showed that the prescription rates of the studied medications were lower in lithium and mirtazapine users and comparable in SSRI/SNRI users, compared to non-users.
PHARMACOPSYCHIATRY
(2022)
Letter
Clinical Neurology
Fumihiko Ueno, Hiroyuki Uchida, Mitsuru Kimura, Akira Yokoyama, Tomoko Yonemoto, Mitsuru Itoh, Yosuke Yumoto, Hideki Nakayama, Sachio Matsushita
PSYCHIATRY AND CLINICAL NEUROSCIENCES
(2022)
Letter
Psychiatry
Masaru Tsukahara, Ryuhei So, Nobuyuki Nomura, Kohei Kitagawa, Yuya Mizuno, Fuminari Misawa, Masafumi Kodama, Hiroyuki Uchida, Masaru Mimura, Hiroyoshi Takeuchi
SCHIZOPHRENIA RESEARCH
(2022)
Review
Biochemistry & Molecular Biology
Masataka Wada, Yoshihiro Noda, Yusuke Iwata, Sakiko Tsugawa, Kazunari Yoshida, Hideaki Tani, Yoji Hirano, Shinsuke Koike, Daiki Sasabayashi, Haruyuki Katayama, Eric Plitman, Kazutaka Ohi, Fumihiko Ueno, Fernando Caravaggio, Teruki Koizumi, Philip Gerretsen, Takefumi Suzuki, Hiroyuki Uchida, Daniel J. Muller, Masaru Mimura, Gary Remington, Anthony A. Grace, Ariel Graff-Guerrero, Shinichiro Nakajima
Summary: This review discusses potential treatments for treatment-resistant schizophrenia, focusing on the therapeutic potential of neuromodulation. It also proposes a multivariate analysis approach that integrates various pathophysiological perspectives, providing a roadmap for future research in this area.
MOLECULAR PSYCHIATRY
(2022)
Review
Pharmacology & Pharmacy
Gentaro Miura, Kouhei Tanaka, Takashi Kemuriyama, Fuminari Misawa, Hiroyuki Uchida, Masaru Mimura, Hiroyoshi Takeuchi
Summary: Clozapine is the gold standard of treatment for patients with treatment-resistant schizophrenia. However, approximately 60% of those patients do not respond to clozapine and the clinical outcomes after clozapine discontinuation are unclear so far.
PHARMACOPSYCHIATRY
(2022)
Letter
Psychiatry
Keisuke Kusudo, Ryo Ochi, Shinichiro Nakajima, Takefumi Suzuki, David Mamo, Fernando Caravaggio, Wanna Mar, Philip Gerretsen, Masaru Mimura, Bruce G. Pollock, Benoit H. Mulsant, Ariel Graff-Guerrero, Tarek K. Rajji, Hiroyuki Uchida
SCHIZOPHRENIA RESEARCH
(2022)
Review
Psychiatry
Kengo Yonezawa, Hideaki Tani, Shinichiro Nakajima, Nobuhiro Nagai, Teruki Koizumi, Tomoyuki Miyazaki, Masaru Mimura, Takuya Takahashi, Hiroyuki Uchida
Summary: This study systematically reviewed postmortem studies on AMPA receptor expressions in schizophrenia and found decreased expression or receptor binding in the hippocampus, while inconsistent findings were observed in other brain regions.
SCHIZOPHRENIA RESEARCH
(2022)
Article
Oncology
Nayuta Higa, Toshiaki Akahane, Taiji Hamada, Hajime Yonezawa, Hiroyuki Uchida, Ryutaro Makino, Shoji Watanabe, Tomoko Takajo, Seiya Yokoyama, Mari Kirishima, Kei Matsuo, Shingo Fujio, Ryosuke Hanaya, Akihide Tanimoto, Koji Yoshimoto
Summary: The study evaluated the mutation profile of the EGFR gene in IDH-wildtype GBMs and found that EGFR alterations are good prognostic markers of overall survival. Also, rare EGFR variants with longitudinal and temporal transformations of EGFRvIII were identified.
Article
Psychology, Clinical
Kie Takahashi, Hiroyuki Uchida, Takefumi Suzuki, Masaru Mimura, Takuto Ishida
Summary: This study examines the proportion of patients with comorbid psychiatric disorders among patients hospitalized for either acute myocardial infarction (AMI) or pulmonary embolism (PE) using a Japanese nationwide database. The results show that PE is a common cause of sudden cardiac arrest (SCA) among psychiatric patients, and the proportions of patients with schizophrenia and mood disorders are significantly higher in the PE group compared to the AMI group.
JOURNAL OF CLINICAL PSYCHIATRY
(2022)
